<DOC>
	<DOCNO>NCT02048150</DOCNO>
	<brief_summary>This pilot clinical trial study best dose anti-prostate specific membrane antigen ( PSMA ) monoclonal antibody MDX1201-A488 ( MDX1201-A488 ) give surgery aid visualization prostate . Attaching fluorescence , substance emits radiation visible , anti-PMSA antibody inject body may help identify tumor specialized microscope use .</brief_summary>
	<brief_title>Intra-operative Optical Imaging With MDX1201-A488 Patients With Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine preferred image dose ( ) , base image quality correlation pathological finding , intravenously administer MDX1201-A488 dose-escalating study ( dose 5 15 mg ) patient moderate high-risk prostate cancer prior undergoing robotic assist laparoscopic prostatectomy ( RALP ) , subject predetermine safety stopping rule . SECONDARY OBJECTIVES : I. Correlate intra-operative optical imaging ( IOOI ) find pre-operative magnetic resonance imaging ( MRI ) find clinical staging . OUTLINE : This dose-escalation study . Patients receive anti-PSMA monoclonal antibody MDX1201-A488 intravenously ( IV ) 30 minute day 1 undergo IOOI RALP day 5 . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate ; patient small cell , neuroendocrine , transitional cell carcinoma eligible Patients consider RALP pelvic lymphadenectomy life expectancy great 10 year determine treat physician Patients moderate highrisk disease define D ' Amico risk stratification least one following : Prostatespecific antigen ( PSA ) level &gt; 10 ng/ml Gleason score &gt; = 7 Clinical stage &gt; = T2c Any performance status Eastern Cooperative Oncology Group ( ECOG ) Men must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry six month follow duration study participation Bone scan without evidence skeletal metastasis Skeletal xray film MRI confirmation absent skeletal metastases bone scan finding equivocal 3Tesla ( T ) multiparametric MRI prostate perform City Hope ( COH ) within 6 week time period prior surgery ; MRI without evidence bladder neck involvement , rectal wall involvement , pelvic lymphadenopathy node &gt; 1 cm White blood cell ( WBC ) within normal limit Hemoglobin ( hgb ) &gt; 10 G/dL Platelet count ( PLT ) &gt; 100 K/uL Creatinine clearance within normal limit Serum glutamic oxaloacetic transaminase ( SGOT ) &lt; 1.5 x upper limit normal ( ULN ) Serum glutamate pyruvate transaminase ( SGPT ) &lt; 1.5 x ULN Bilirubin &lt; 1.5 x ULN All subject must ability understand willingness sign write informed consent Patients uncontrolled illness include ongoing active infection Prior treatment prostate cancer include brachytherapy , radiation therapy , cryosurgery , highintensity focus ultrasound ( HIFU ) , vaccine therapy Prior pelvic surgery radiation Urinary incontinence require condom catheter use &gt; = 1 pad/day Prior antiincontinence surgery Use neoadjuvant hormonal manipulation History active coexisting nonprostatic malignancy except basal cell skin cancer squamous cell skin cancer Subjects , opinion investigator , may able comply safety monitoring requirement study</criteria>
	<gender>Male</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>